Stock-Based Compensation | Stock-Based Compensation Equity Incentive Plan 2021 Equity Incentive Plan. In October 2021, The Company’s Board of Directors and stockholders adopted the 2021 Equity Incentive Plan (the “2021 Plan”) and it was approved by stockholders in October 2021. The 2021 Plan replaced our 2011 Plan. However, awards outstanding under our 2011 Plan will continue to be governed by their existing terms. The 2021 Plan has the features described below. Share Reserve. The number of shares of our common stock available for issuance under our 2021 Plan equals the sum of 5,262,500 shares plus up to approximately 13,719,000 shares subject to awards granted under our 2011 Plan that expire, forfeit or are repurchased following the effective date of the 2021 Plan. The number of shares reserved for issuance under our 2021 Plan will be increased automatically on the first business day of each of our fiscal years, commencing in 2022 and ending in 2031, by a number equal to the least of (i) 4,784,100 shares, (ii) 5% of the shares of common stock outstanding on the last business day of the prior fiscal year; or (iii) the number of shares determined by the Board of Directors. During the three months ended March 31, 2022 the Company increased the number of shares reserved under the 2021 Plan by 1,519,241 pursuant to this evergreen provision. In general, to the extent that any awards under the 2021 Plan are forfeited, terminate, expire or lapse without the issuance of shares, or if we reacquire the shares subject to awards granted under our 2021 Plan, those shares will again become available for issuance under our 2021 Plan, as will shares applied to pay the exercise or purchase price of an award or to satisfy tax withholding obligations related to any award. Stock Options Stock Options. Stock options granted under the Plan generally vest based on continued service over four years and expire ten years from the date of grant. A summary of equity award activity under the Company’s equity plans and related information is as follows (in thousands, except share, price and year data): Shares Outstanding Weighted- Weighted- Aggregate Balance as of December 31, 2021 3,880,274 14,940,182 $ 5.19 6.69 $ 182,843 Shares authorized 1,519,241 Options granted (109,800) 109,800 13.29 Options exercised — (429,639) 2.06 Options cancelled 221,176 (221,176) 5.54 Restricted Stock Units (“RSUs”) granted (897,224) RSUs cancelled 7,525 Balance as of March 31, 2022 4,621,192 14,399,167 $ 5.34 6.54 $ 93,993 Vested and exercisable as of March 31, 2022 8,575,879 $ 2.26 4.88 $ 72,090 The weighted-average grant-date fair value of options granted was $13.29 and $4.53 during the three months ended March 31, 2022 and 2021, respectively. The intrinsic value of options exercised for the three months ended March 31, 2022 and 2021 was $4.1 million and $0.3 million, respectively. Aggregate intrinsic value represents the difference between the exercise price of the options and the estimated fair value of the Company’s common stock. The aggregate grant-date fair value of options vested was $1.8 million and $0.7 million during the three months ended March 31, 2022 and 2021, respectively. The following table summarizes the Black-Scholes option pricing model weighted-average assumptions used in estimating the fair value of stock options granted to employees during the three months ended March 31, 2022 and 2021. Three Months Ended March 31, 2022 2021 Expected term (in years) 6.0 6.0 Expected volatility 49.0 % 49.2 % Risk-free interest rate 1.20 % 1.09 % Expected dividend yield — % — % Expected term. For stock options considered to be “plain vanilla” options, the Company estimates the expected term based on the simplified method, which is essentially the weighted average of the vesting period and contractual term, as the Company’s historical share option exercise experience does not provide a reasonable basis upon which to estimate the expected term. Expected volatility. The Company performed an analysis using the average volatility of a peer group of representative public companies with sufficient trading history over the expected term to develop an expected volatility assumption. Risk-free interest rate. Based upon quoted market yields for the United States Treasury debt securities for a term consistent with the expected life of the awards in effect at the time of grant. Expected dividend yield. Because the Company has never paid and has no intention to pay cash dividends on common stock, the expected dividend yield is zero. Fair value of underlying common stock. Prior to the IPO, because the Company’s common stock was not yet publicly traded, the Company estimated the fair value of common stock. The Board considered numerous objective and subjective factors to determine the fair value of the Company’s common stock at each meeting in which awards are approved. The factors considered include, but are not limited to: (i) the results of contemporaneous independent third-party valuations of the Company’s common stock; (ii) the prices, rights, preferences, and privileges of the Company’s convertible preferred stock relative to those of its common stock; (iii) the lack of marketability of the Company’s common stock; (iv) actual operating and financial results; (v) current business conditions and projections; (vi) the likelihood of achieving a liquidity event, such as an initial public offering or sale of the Company, given prevailing market conditions; and (vii) precedent transactions involving the Company’s shares. Restricted Stock Units During November 2021, in connection with the IPO, the Company granted its first RSUs under the 2021 Plan to certain of its non-employee directors. During the three months ended March 31, 2022, the Company began granting more RSUs than options to its employees. All RSUs granted have service-based vesting conditions. RSUs granted under the 2021 Equity Incentive Plan generally vest based on continued service over a three four RSU activity for the three months ended March 31, 2022 was as follows: Shares Weighted-Average Grant Date Fair Value per Share Unvested balance as of December 31, 2021 18,750 $22.04 Granted 897,224 $11.50 Vested — $— Forfeited (7,525) $13.29 Unvested balance as of March 31, 2022 908,449 $11.70 ESPP In October 2021, the Company’s Board of Directors adopted the 2021 Employee Stock Purchase Plan (“ESPP”), which became effective on the date of the IPO. The ESPP initially reserved and authorized the issuance of up to a total of 956,800 shares of Class A common stock to participating employees. During the three months ended March 31, 2022, the Company increased the number of shares reserved under the ESPP by 607,696 pursuant to its evergreen provision. The initial offering period commenced in November 2021 and the first purchase date will occur in May 2022. Under the Company’s ESPP, eligible employees may authorize payroll deductions of up to 50% of their eligible compensation, subject to IRS limitations, during prescribed offering periods to purchase shares of the Company’s common stock at a price per share equal to 85% of the lesser of (1) the stock price at the employee’s first participation in the offering period or (2) the fair market value of the Company’s common stock on the purchase date. A participant may participate in only one offering period at a time, and a new offering period generally begins each May 20th and November 20th. Each offering period is generally 24 months and consists of four exercise dates (each, generally six months following the start of the offering period or the preceding exercise date, as the case may be). If the fair market value of the Company’s common stock is less on a given exercise date than on the date of grant, employee participation in that offering period ends and participants are automatically re-enrolled in the next new offering period. The ESPP shall terminate automatically 20 years after its effective date, unless the ESPP is extended by the Board and the extension is approved within 12 months by a vote of the stockholders of the Company. There were no shares purchased by employees during the three months ended March 31, 2022, as the first purchase date will occur in May 2022. The fair value of the purchase rights under the ESPP plan was estimated using the Black-Scholes option pricing model with a similar methodology for determining inputs as the Company’s stock options, as described above. The Company recorded stock-based compensation expense under this plan of $0.8 million for the three months ended March 31, 2022. As of March 31, 2022, approximately $1.6 million had been withheld on behalf of employees, respectively. The following table summarizes the Black-Scholes option pricing model assumptions used in estimating the fair value of the stock purchase rights under the ESPP Plan during the three months ended March 31, 2022. Three Months Ended March 31, 2022 Expected term (in years) 0.5 - 2.0 Expected volatility 45% - 57% Risk-free interest rate 0.10% - 0.51% Expected dividend yield — % Stock-Based Compensation Expense Stock-based compensation expense included in the condensed statements of operations was as follows (in thousands): For the Three Months Ended March 31, 2022 2021 Cost of revenue $ 276 $ 85 Research and development 1,555 399 Sales and marketing 1,134 189 General and administrative 870 235 Total stock-based compensation expense $ 3,835 $ 908 During the three months ended March 31, 2022 and 2021, the Company capitalized $0.4 million and $0.1 million, respectively, of stock-based compensation for the development of internal-use software. As of March 31, 2022, total compensation cost related to stock options not yet vested was approximately $29.8 million, which will be recognized over a weighted-average period of approximately 3 years. During the three months ended March 31, 2022 , the Company’s Compensation Committee approved a new bonus plan for its employees. The bonus plan is contingent upon the achievement of annual corporate performance targets. If these performance targets are met during 2022, employees will be paid out under the plan in RSUs in 2023. As a result, the Company recognized $0.5 million in stock-based compensation during the three months ended March 31, 2022 based on progress made towards these performance targets. During the three months ended March 31, 2021, the Company’s Board approved modifications to extend the exercise period of vested options for certain terminated employees by the earlier of five years from the employee’s termination date or the option expiration date. The modification was effective upon the Board’s approvals, which resulted in incremental stock-based compensation expense during March 31, 2021. As a result, the Company recognized an incremental $0.1 million in stock-based compensation during the three months ended March 31, 2021. There were no such modifications during the three months ended March 31, 2022 . |